| Autor: |
Kamel Debbi, Davorin Radosavljevic, Vladimir Todorovic, Aziz Cherif, Semir Beslija, Milan Risteski, Fady Geara, Dusanka Tesanovic, Siniša Radulović, Damir Vrbanec, Liljana Stamatovic, Gabriele Coraggio, Mladen Filipovic, Ivan Marković, Salvador Villà Freixa, Hassan Errihani, Oliver Arsovski, Giorgio Mustacchi, Jean Pierre Lotz, Radan Dzodic, Igor Stojkovski, Adda Bounedjar, Yazid Belkacemi, Lazar Popovic, Marco Krengli, Marie Pierre Chauvet, R Samlali, Jean Philippe Spano, Nino Vasev, Sahar Ghith, Nina Radosevic, Ahmed Idbaih, Alphonse G. Taghian, Mahmut Ozsahin, Noémie Grellier, K. Bouzid, Abraham Kuten, Farouk Benna, Hamouda Boussen, Joseph Gligorov, Hahn To, Suzana Vasovic, Khaldoun Kerrou, Sedat Turkan, Karima Mokhtari, Pauletta G. Tsoutsou, V. Kovcin, Souha Sahraoui |
| Jazyk: |
angličtina |
| Rok vydání: |
2020 |
| Předmět: |
|
| Zdroj: |
European Journal of Cancer
European Journal of Cancer, Vol. 135 (2020) pp. 130-146
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
European journal of cancer, vol. 135, pp. 130-146 |
| ISSN: |
0959-8049 |
| DOI: |
10.1016/j.ejca.2020.05.015 |
| Popis: |
Coronavirus disease 2019 (COVID-19) is an infectious disease caused by a new virus that has never been identified in humans before. COVID-19 caused at the time of writing of this article, 2.5 million cases of infections in 193 countries with 165,000 deaths, including two-third in Europe. In this context, Oncology Departments of the affected countries had to adapt quickly their health system care and establish new organizations and priorities. Thus, numerous recommendations and therapeutic options have been reported to optimize therapy delivery to patients with chronic disease and cancer. Obviously, while these cancer care recommendations are immediately applicable in Europe, they may not be applicable in certain emerging and low- and middle-income countries (LMICs). In this review, we aimed to summarize these international guidelines in accordance with cancer types, making a synthesis for daily practice to protect patients, staff and tailor anti-cancer therapy delivery taking into account patients/tumour criteria and tools availability. Thus, we will discuss their applicability in the LMICs with different organizations, limited means and different constraints.
Highlights • The first recommendations concerned mainly staff and patients with cancer protection. • More than half of the worldwide cancers are diagnosed in low- and middle-income countries (LMICs). • Organization in accordance with available means: main key for anti-cancer strategy in LMICs. • European recommendations applicability for coronavirus disease 2019 (COVID-19) pandemic is questioned in LMICs. • Amplification of pandemic effects on both COVID and cancer is to be feared in LMICs. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect 